18-Sep-2024
Globe Newswire (Thu, 19-Sep 8:00 AM ET)
Buy Rating Affirmed for Arcutis Biotherapeutics Amid Positive Dermatology Market Signals
TipRanks (Thu, 19-Sep 6:17 AM ET)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 5-Sep 4:00 PM ET)
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
Globe Newswire (Thu, 5-Sep 8:00 AM ET)
Globe Newswire (Wed, 28-Aug 8:00 AM ET)
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Globe Newswire (Thu, 22-Aug 8:00 AM ET)
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
Globe Newswire (Wed, 14-Aug 4:00 PM ET)
Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
Globe Newswire (Thu, 1-Aug 4:00 PM ET)
Arcutis Announces ZORYVE U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
Globe Newswire (Mon, 29-Jul 7:35 AM ET)
Arcutis Launches ZORYVE (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
Globe Newswire (Mon, 29-Jul 7:30 AM ET)
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Arcutis Biotherapeutics trades on the NASDAQ stock market under the symbol ARQT.
As of September 18, 2024, ARQT stock price climbed to $10.40 with 2,412,628 million shares trading.
ARQT has a beta of 2.10, meaning it tends to be more sensitive to market movements. ARQT has a correlation of 0.07 to the broad based SPY ETF.
ARQT has a market cap of $1.22 billion. This is considered a Small Cap stock.
Last quarter Arcutis Biotherapeutics reported $31 million in Revenue and -$.42 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.15.
In the last 3 years, ARQT stock traded as high as $27.40 and as low as $1.76.
The top ETF exchange traded funds that ARQT belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
ARQT has outperformed the market in the last year with a return of +61.7%, while the SPY ETF gained +27.7%. In the last 3 month period, ARQT beat the market returning +27.6%, while SPY returned +2.7%. However, in the most recent 2 weeks ARQT has underperformed the stock market by returning -0.6%, while SPY returned +1.9%.
ARQT support price is $9.85 and resistance is $10.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARQT stock will trade within this expected range on the day.